Comparative Pharmacology
Head-to-head clinical analysis: ANGIOVIST 370 versus MAGNEVIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGIOVIST 370 versus MAGNEVIST.
ANGIOVIST 370 vs MAGNEVIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiovist 370 (diatrizoate meglumine) is a water-soluble iodinated radiographic contrast agent that attenuates X-rays, thereby enhancing the contrast of vascular structures and organs during imaging procedures.
Gadopentetate dimeglumine is a paramagnetic contrast agent that shortens T1 and T2 relaxation times in tissues where it accumulates, enhancing signal intensity on T1-weighted magnetic resonance imaging (MRI). It distributes extracellularly and does not cross the intact blood-brain barrier, but accumulates in areas of disrupted barrier or abnormal vascularity.
Intravenous injection: 1-2 mL/kg (370 mg I/mL) up to 150 mL total for CT imaging; intra-arterial injection: 5-80 mL depending on procedure. Rate: 1-5 mL/sec.
0.2 mL/kg (0.1 mmol/kg) intravenously, up to 0.6 mL/kg (0.3 mmol/kg) for certain indications, with a maximum of 20 mL per dose.
None Documented
None Documented
Terminal elimination half-life approximately 2 hours; prolonged in renal impairment (up to 30-40 hours in severe impairment).
Terminal elimination half-life in patients with normal renal function is approximately 1.6 hours. In patients with impaired renal function, half-life is prolonged (up to 30 hours with GFR <30 mL/min).
Primarily renal excretion of unchanged drug via glomerular filtration; approximately 95% eliminated in urine within 24 hours, with less than 1% biliary/fecal.
Renal excretion of unchanged gadopentetate dimeglumine accounts for approximately 99% of the administered dose within 72 hours. Biliary/fecal excretion is negligible (<0.5%).
Category C
Category C
Contrast Agent
Contrast Agent